Pharmacy benefit manager Medco Health Solutions faced a barrage of class action lawsuits and government enforcement actions alleging it steered patients toward expensive branded drugs — not because those drugs were better, but because Medco pocketed larger rebates from manufacturers. The resulting legal actions produced more than $200 million in combined settlements, including a landmark $155 million federal False Claims Act recovery in 2006, a $29.3 million multistate settlement with 20 attorneys general over deceptive drug-switching practices, and additional kickback resolutions that continued even after Medco merged with Express Scripts in 2012.
The accusations painted a picture of a company that managed prescription benefits for over 65 million Americans while quietly manipulating which drugs those patients received. Medco allegedly contacted physicians to recommend switching patients to different medications, claiming the changes would save money, when in reality the switches often moved patients from cheaper generics to costlier branded alternatives that generated higher rebate payments for Medco.
Table of Contents
- How Did Medco Allegedly Steer Patients to High-Margin Branded Drugs Through Its PBM Role?
- What Were the Financial Penalties and Settlement Terms Medco Faced?
- The Ohio Case and State-Level Enforcement Actions
- What the Settlement Prohibited and Why Those Restrictions Matter
- The Whistleblower Role and Limitations of False Claims Act Enforcement
- The Express Scripts Merger and Post-Merger Accountability
- What the Medco Cases Mean for PBM Oversight Going Forward
- Frequently Asked Questions
How Did Medco Allegedly Steer Patients to High-Margin Branded Drugs Through Its PBM Role?
Medco operated as a middleman between drug manufacturers, health insurance plans, and patients. In that role, it negotiated rebates from pharmaceutical companies — essentially volume discounts paid to the PBM in exchange for favorable placement on formularies. The federal government alleged that Medco crossed the line from legitimate formulary management into fraud by soliciting and accepting kickbacks from manufacturers to favor their drugs, then submitting false claims to government healthcare programs. The scheme was first exposed through two whistleblower lawsuits: one filed in 1999 by George Bradford Hunt and Walter Gauger, and another in 2000 by Dr. Joseph Piacentile.
These cases were eventually consolidated and led to the $155 million federal settlement announced on October 23, 2006. The drug-switching component was particularly insidious. According to the 20-state attorneys general investigation, Medco would contact physicians and recommend that patients be switched from one medication to another within the same therapeutic class — cholesterol drugs being a prominent example. Medco represented these switches as cost-saving measures for patients. What the company failed to disclose was that the recommended drugs often came with higher manufacturer rebates paid to Medco, and that the switches sometimes moved patients away from medications with available generic equivalents to branded drugs without generics. A patient stable on a cholesterol medication might find their prescription changed not because of any clinical benefit, but because Medco stood to collect a larger rebate on the replacement drug.
What Were the Financial Penalties and Settlement Terms Medco Faced?
The financial consequences were substantial by the standards of the era, though critics argued they still represented a fraction of the profits Medco earned through the alleged schemes. The federal False Claims Act settlement of $155 million plus interest, announced in 2006, grew to approximately $184.1 million when combined with state recoveries — making it the largest False Claims Act recovery from a pharmacy benefit manager at that time. The settlement resolved allegations of false claims submission, kickback solicitation from manufacturers, and improper payments to health plans to secure contracts. The 2004 multistate settlement added another $29.3 million. That sum broke down into $20.2 million in cy pres restitution (funds directed to public health or consumer protection programs rather than individual claimants), $2.5 million paid directly to identifiable patients who incurred out-of-pocket costs from cholesterol drug switches between 1999 and 2004, and $6.6 million for attorneys general fees and investigation costs.
However, the relatively small direct-to-patient payment highlights a limitation common in these cases: most affected consumers never saw individual restitution. If you were a patient switched from one cholesterol drug to another during that period and paid higher copays as a result, you may have been among those who received a share of the $2.5 million pool — but with potentially thousands of affected patients, individual payments were modest. The litigation did not end there. In 2015, three years after Medco merged into express scripts in a $29.1 billion deal, the successor company paid $7.9 million to resolve separate kickback allegations involving undisclosed payments from drug manufacturers. This later resolution demonstrates that the legal tail of PBM misconduct can extend well beyond the original company’s existence.
The Ohio Case and State-Level Enforcement Actions
Ohio’s case against Medco stands out for its specificity and courtroom outcome. In 2003, Ohio sued Medco for overcharging the State Teachers Retirement System by tens of millions of dollars through inflated dispensing fees and by steering patients, pharmacists, and physicians toward higher-cost drugs rather than pursuing the least expensive options. Unlike the federal and multistate cases, which ended in negotiated settlements, the Ohio matter went to trial. In 2005, Medco was found liable and ordered to pay $7.8 million in damages. The Ohio litigation is instructive because it showed what happened when the allegations were tested in open court rather than resolved behind closed doors. The state proved that Medco’s conduct went beyond aggressive business practices and constituted actionable misconduct.
For the State Teachers Retirement System, the overcharges meant that pension funds — money set aside for retired educators — were being siphoned away through inflated drug costs. This kind of concrete, identifiable harm made the Ohio case a powerful example of how PBM practices could affect specific populations, not just abstract healthcare spending numbers. State-level enforcement varied significantly. Maine’s attorney general filed a detailed complaint referencing the Ohio litigation and outlining similar concerns. But not every state took action, and the patchwork nature of state enforcement meant that identical PBM practices might face scrutiny in one jurisdiction and go unchallenged in another. This remains a structural limitation in PBM oversight: the regulatory landscape is fragmented, and consumers in different states receive uneven protection.
What the Settlement Prohibited and Why Those Restrictions Matter
The 2004 multistate settlement imposed specific restrictions on Medco’s drug-switching practices that serve as a useful benchmark for evaluating PBM conduct. Under the agreement, Medco was barred from soliciting drug switches when the proposed drug costs more than the prescribed drug, when the prescribed drug has a generic equivalent and the proposed drug does not, when the switch is made to avoid generic competition, or when the switch occurs more than once in two years within a therapeutic class for any patient. These prohibitions essentially defined the line between legitimate formulary management and self-dealing. A PBM recommending a switch from a branded drug to its generic equivalent is performing a genuine cost-saving function. A PBM recommending a switch from a generic to a branded drug with no generic alternative — while collecting higher rebates on the branded option — is exploiting its position.
The two-year limit on therapeutic-class switches was particularly notable, as it addressed the practice of repeatedly shuffling patients between drugs as new rebate deals were struck with different manufacturers. The tradeoff, however, is that these restrictions applied only to Medco and only as a result of the specific settlement. They did not create industry-wide rules. Other PBMs could and did continue similar practices without facing the same constraints. Patients comparing their PBM’s behavior to the Medco settlement terms would find that the protections were company-specific rather than universal, illustrating the difference between a settlement and a regulation.
The Whistleblower Role and Limitations of False Claims Act Enforcement
The federal case against Medco began not with a government investigation but with private citizens using the False Claims Act’s qui tam provisions. George Bradford Hunt, Walter Gauger, and Dr. Joseph Piacentile filed separate whistleblower lawsuits in 1999 and 2000, which were later consolidated. Under the False Claims Act, whistleblowers who expose fraud against the government can receive a share of any resulting recovery — a powerful financial incentive that has driven billions of dollars in healthcare fraud recoveries over the decades. The Medco case demonstrated both the power and the limitations of this approach. The power: without insiders willing to risk their careers and file suit, the alleged schemes might never have come to light. Federal investigators often lack the resources or access to uncover complex PBM rebate arrangements on their own.
The limitation: qui tam cases move slowly. The whistleblower suits were filed in 1999 and 2000, but the settlement was not announced until October 2006 — a seven-year timeline during which the alleged practices continued. Patients affected during those years had no mechanism to halt the conduct in real time. There is also the question of deterrence. The $184.1 million total federal and state recovery was the largest False Claims Act recovery from a PBM when it was announced, but Medco reported annual revenues in the tens of billions of dollars. When the penalty represents a small percentage of the profits generated by the underlying conduct, the deterrent effect is debatable. Companies may treat settlements as a cost of doing business rather than a reason to change their practices — a concern that has persisted across the pharmaceutical and PBM industries.
The Express Scripts Merger and Post-Merger Accountability
Medco Health Solutions ceased to exist as an independent company in 2012 when it merged with Express Scripts in a $29.1 billion transaction, creating one of the largest PBMs in the country. The merger raised immediate questions about whether the combined entity would carry forward the behavioral restrictions imposed on Medco through its various settlements, and whether outstanding legal liabilities would be adequately addressed.
The 2015 kickback resolution — in which Express Scripts paid $7.9 million to settle allegations involving Medco-era undisclosed payments from drug manufacturers — confirmed that merger does not erase legal exposure. But it also illustrated a practical difficulty for consumers and regulators: when a company is absorbed into a larger entity, the institutional memory of the misconduct fades, and the specific compliance commitments negotiated in settlements can become harder to monitor and enforce. Patients who dealt with Medco before the merger may find it difficult to trace their prescription history or determine whether they were affected by the drug-switching practices at issue in the earlier cases.
What the Medco Cases Mean for PBM Oversight Going Forward
The Medco litigation was among the earliest and most prominent challenges to PBM drug-switching practices, but the underlying business model it exploited — opaque manufacturer rebates flowing to PBMs that control which drugs patients receive — remains largely intact across the industry. Legislative and regulatory efforts to increase PBM transparency have gained momentum in recent years, with proposals at both federal and state levels to require disclosure of rebate amounts, ban spread pricing, and impose fiduciary duties on PBMs. Whether those efforts produce meaningful change or follow the familiar pattern of incremental reform remains to be seen.
For consumers, the Medco case serves as a reminder that the entity managing your prescription benefits has financial interests that may not align with your own. The settlements established that a PBM recommending a drug switch is not necessarily acting in your interest — it may be acting in its own. That skepticism, grounded in the documented record of this litigation, is a reasonable starting point for anyone navigating the pharmacy benefit system today.
Frequently Asked Questions
Are there any active Medco class action settlements I can file a claim for?
No. The major Medco settlements were finalized between 2004 and 2015, and the claims filing deadlines have long passed. Medco merged with Express Scripts in 2012 and no longer exists as an independent company.
How much money did Medco pay in total across all settlements?
The combined recoveries exceeded $200 million, including approximately $184.1 million in federal and state False Claims Act recoveries, $29.3 million in the 20-state drug-switching settlement, $7.8 million from the Ohio trial verdict, and $7.9 million in a 2015 post-merger kickback resolution.
What drugs were involved in the Medco drug-switching allegations?
The 20-state settlement specifically identified cholesterol drugs as a category where Medco steered patients from one medication to another while collecting higher manufacturer rebates. The federal case involved broader allegations of favoring drugs from manufacturers that paid kickbacks.
Did individual patients receive money from the Medco settlements?
In the 20-state settlement, $2.5 million was paid directly to identifiable patients who incurred costs from cholesterol drug switches between 1999 and 2004. The majority of the recovery — $20.2 million — went to cy pres restitution benefiting public health programs rather than individual claimants.
What happened to Medco after the settlements?
Medco Health Solutions merged with Express Scripts in 2012 in a $29.1 billion deal. Express Scripts itself was later acquired by Cigna in 2018. The legal obligations from Medco’s settlements carried over to the successor entities, as demonstrated by the 2015 kickback resolution paid by Express Scripts for Medco-era conduct.